Immatics (IMTX) Accumulated Expenses (2023 - 2026)
Immatics (IMTX) posted Accumulated Expenses of $21.5 million for Q4 2025, up 31.17% sequentially from $16.4 million in Q2 2025, and up 90.38% YoY from $11.3 million in Q4 2024.
Analysis
Immatics (IMTX) Accumulated Expenses (2023 - 2026) Analysis & Trends
Immatics has reported Accumulated Expenses for 3 years, with the latest figure at $21.5 million in Q4 2025.
- Quarterly Accumulated Expenses rose 90.38% year-over-year to $21.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.5 million (up 90.38% YoY) and the FY2025 annual result came in at $20.9 million, up 82.43% from the prior year.
- Accumulated Expenses grew to $21.5 million in Q4 2025 per IMTX's latest filing, from $16.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $21.5 million in Q4 2025 and troughed at $11.3 million in Q4 2024.
- A 3-year average of $17.0 million and a median of $17.6 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses slumped 40.09% in 2024, then surged 90.38% in 2025.
- Over 3 years, Accumulated Expenses stood at $18.9 million in 2023, then sank by 40.09% to $11.3 million in 2024, then soared by 90.38% to $21.5 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $21.5 million, $16.4 million, and $11.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.28 Mn |
| Dec 31, 2025 | 21.53 Mn |
| Jun 30, 2025 | 16.41 Mn |
| Dec 31, 2024 | 11.31 Mn |
| Dec 31, 2023 | 18.87 Mn |